265 related articles for article (PubMed ID: 31807967)
1. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
2. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kobayashi K; Sugiyama E; Shinozaki E; Wakatsuki T; Tajima M; Kidokoro H; Aoyama T; Nakano Y; Kawakami K; Hashimoto K; Suenaga M; Ichimura T; Ogura M; Chin K; Nakayama I; Ooki A; Takahari D; Suzuki W; Yokokawa T; Minowa Y; Hiraoka T; Suzuki K; Sato H; Hama T; Yamaguchi K
Cancer Chemother Pharmacol; 2021 Jun; 87(6):767-777. PubMed ID: 33635392
[TBL] [Abstract][Full Text] [Related]
3. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
[TBL] [Abstract][Full Text] [Related]
6. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms.
Maeda A; Irie K; Ando H; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Aoki M; Inaguma K; Kajita M; Fujimura A; Fukushima S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):107-113. PubMed ID: 30368586
[TBL] [Abstract][Full Text] [Related]
7. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients.
Kubota Y; Fujita KI; Takahashi T; Sunakawa Y; Ishida H; Hamada K; Ichikawa W; Tsunoda T; Shimada K; Masuo Y; Kato Y; Sasaki Y
Clin Pharmacol Ther; 2020 Sep; 108(3):586-595. PubMed ID: 32034953
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors.
Thangaraju P; Singh H; Chakrabarti A
Indian J Cancer; 2015; 52(3):257-60. PubMed ID: 26905101
[TBL] [Abstract][Full Text] [Related]
10. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics.
Sunakawa Y; Furuse J; Okusaka T; Ikeda M; Nagashima F; Ueno H; Mitsunaga S; Hashizume K; Ito Y; Sasaki Y
Invest New Drugs; 2014 Feb; 32(1):104-12. PubMed ID: 23553067
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
[TBL] [Abstract][Full Text] [Related]
17. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
Chan SL; Ma BB
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
[TBL] [Abstract][Full Text] [Related]
18. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
[TBL] [Abstract][Full Text] [Related]
19. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
[TBL] [Abstract][Full Text] [Related]
20. Regorafenib in the treatment of metastatic colorectal cancer.
de la Fouchardière C
Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
